Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 4Carcinoma 4Stomach Neoplasms 3Peritoneal Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 3Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1Ascites 1Adenocarcinoma 1

Interventions

Quality of Life 2Nutritional Status 2Interviews as Topic 2sintilimab 1danvatirsen 1contrast agent BR1 1catumaxomab 1aflibercept 1Zoledronic Acid 1Vascular Access Devices 1Portasystemic Shunt, Transjugular Intrahepatic 1Octreotide 1Hyperthermic Intraperitoneal Chemotherapy 1Catheters, Indwelling 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ascites × catumaxomab × Clear all
NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed
32 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡